Johnson & Johnson (NYSE:JNJ) Trading Up 1.9% – What’s Next?

Johnson & Johnson (NYSE:JNJ) shares shot up 1.9% on Tuesday . The company traded as high as $214.39 and last traded at $213.7790. 10,819,306 shares were traded during mid-day trading, an increase of 30% from the average session volume of 8,347,143 shares. The stock had previously closed at $209.72.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Delaware’s top court tossed part of a $1 billion damages award tied to J&J’s abandoned Auris Health deal and ordered a recalculation of damages, which materially reduces potential liability uncertainty. Court Orders Recalculation Of Damages In Johnson & Johnson Auris Case
• Positive Sentiment: J&J reported strong long-term Rybrevant results in metastatic colorectal cancer (RAS/BRAF wild-type) presented at ASCO — a clinical win that can boost oncology revenue potential and support valuation of the cancer franchise. Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial
• Positive Sentiment: New Phase 3 analyses for CAPLYTA and other depression treatments will be presented at ACNP, underscoring ongoing psychiatric pipeline progress that could support future specialty sales. Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
• Positive Sentiment: Quarterly commentary and investor letters highlight drivers that lifted JNJ in Q4 (diversified pharma and MedTech momentum), reinforcing the narrative of steady underlying performance. Here’s What Lifted Johnson & Johnson (JNJ) in Q4
• Neutral Sentiment: J&J presented at the J.P. Morgan Healthcare Conference; the transcript provides management’s strategic outlook and may influence short-term investor positioning but contains no single market-moving surprise. Johnson and Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Analysts note MedTech momentum driven by cardiovascular strength and new product rollouts — a supportive growth narrative ahead of Q4 results, though the update is forward-looking rather than immediate earnings news. What’s Powering J&J’s MedTech Growth Ahead of Q4 Release?
• Negative Sentiment: Outlook risk: the same MedTech coverage also flags lingering pressure in China that could weigh on near-term MedTech sales growth and margins in upcoming quarters. What’s Powering J&J’s MedTech Growth Ahead of Q4 Release?

Analyst Upgrades and Downgrades

Several brokerages recently commented on JNJ. Wolfe Research increased their price objective on shares of Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research note on Monday, January 5th. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Stifel Nicolaus raised their price objective on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. Wells Fargo & Company upped their target price on Johnson & Johnson from $212.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Finally, Loop Capital set a $190.00 price target on Johnson & Johnson in a research note on Wednesday, October 22nd. Four analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $213.33.

Johnson & Johnson Trading Up 1.9%

The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The firm has a market cap of $515.06 billion, a price-to-earnings ratio of 20.64, a price-to-earnings-growth ratio of 2.10 and a beta of 0.34. The firm’s fifty day moving average is $203.34 and its 200-day moving average is $185.38.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.4%. Johnson & Johnson’s payout ratio is 50.19%.

Institutional Trading of Johnson & Johnson

Hedge funds have recently modified their holdings of the stock. Abich Financial Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the third quarter valued at about $26,000. Evolution Wealth Management Inc. acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $27,000. Clayton Financial Group LLC bought a new position in Johnson & Johnson in the third quarter worth approximately $28,000. Semmax Financial Advisors Inc. grew its stake in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares during the period. Finally, GFG Capital LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $35,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.